top of page
History
Present
2022. 04
Cartisome®: IND submission to MFDS in Korea
for a phase 1 clinical trial
2021. 12
DAEWOONG PHARMACEUTICAL CO.,LTD.
joined as a Strategic Investor
2021. 10
Raised KRW 10 billion in a Series B funding
2021. 07
EST-SFX-T: got a Phase 1b/2a clinical trial approval
by MFDS in Korea
2020. 06
Signed a contract with DAISHIN Securities Co., Ltd. as a IPO lead underwriter
2019. 09
Opened R&D Center in Pangyo
2019. 06
Raised KRW 4 billion in a Series A funding
2016. 09
Opened R&D Center in Ansan
2016. 03
Founded EXOSTEMTECH Co., Ltd.
2016
bottom of page